A systematic review of factors affecting medication adherence among patients with osteoporosis

被引:122
作者
Yeam, C. T. [1 ]
Chia, S. [1 ]
Tan, H. C. C. [1 ]
Kwan, Y. H. [1 ,2 ]
Fong, W. [1 ,3 ,4 ]
Seng, J. J. B. [1 ]
机构
[1] Duke NUS Med Sch, 8 Coll Rd, Singapore 169857, Singapore
[2] Duke NUS Med Sch, Program Hlth Serv & Syst Res, 8 Coll Rd, Singapore 169857, Singapore
[3] Singapore Gen Hosp, Dept Rheumatol & Immunol, Outram Rd, Singapore 169608, Singapore
[4] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore
关键词
Anti-osteoporotic therapy; Medication adherence; Osteoporosis; Patient compliance; Bisphosphonates; ORAL BISPHOSPHONATE THERAPY; HORMONE REPLACEMENT THERAPY; LONG-TERM PERSISTENCE; QUALITY-OF-LIFE; POSTMENOPAUSAL OSTEOPOROSIS; DOSING FREQUENCY; UNITED-STATES; VITAMIN-D; INTRAVENOUS IBANDRONATE; TREATMENT SATISFACTION;
D O I
10.1007/s00198-018-4759-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Summary The aim of this review was to identify factors that influence patients' adherence to anti-osteoporotic therapy. Factors identified that were associated with poorer medication adherence included polypharmacy, older age, and misconceptions about osteoporosis. Physicians need to be aware of these factors so as to optimize therapeutic outcomes for patients.IntroductionTo identify factors that influence patients' adherence to anti-osteoporotic therapy.MethodsA systematic review of literature was performed for articles published up till January 2018 using PubMed (R), PsychINFO (R), Embase (R), and CINAHL (R). Peer-reviewed articles which examined factors associated with anti-osteoporotic medication adherence were included. Classes of anti-osteoporotic therapy included bisphosphonates, parathyroid hormone-related analogue, denosumab, selective estrogen receptor modulators, estrogen/progestin therapy, calcitonin, and strontium ranelate. Meta-analyses, case reports/series, and other systematic reviews were excluded. Identified factors were classified using the World Health Organization's five dimensions of medication adherence (condition, patient, therapy, health-system, and socio-economic domains).ResultsOf 2404 articles reviewed, 124 relevant articles were identified. The prevalence of medication adherence ranged from 12.9 to 95.4%. Twenty-four factors with 139 sub-factors were identified. Bisphosphonates were the most well-studied class of medication (n=59, 48%). Condition-related factors that were associated with poorer medication adherence included polypharmacy, and history of falls was associated with higher medication adherence. Patient-related factors which were associated with poorer medication adherence included older age and misconceptions about osteoporosis while therapy-related factors included higher dosing frequency and medication side effects. Health system-based factors associated with poorer medication adherence included care under different medical specialties and lack of patient education. Socio-economic-related factors associated with poorer medication adherence included current smoker and lack of medical insurance coverage.ConclusionThis review identified factors associated with poor medication adherence among osteoporotic patients. To optimize therapeutic outcomes for patients, clinicians need to be aware of the complexity of factors affecting medication adherence.
引用
收藏
页码:2623 / 2637
页数:15
相关论文
共 137 条
  • [1] Abobului M, 2015, J Med Life, V8 Spec Issue, P119
  • [2] Persistence with teriparatide in patients with osteoporosis: the UK experience
    Arden, N. K.
    Earl, S.
    Fisher, D. J.
    Cooper, C.
    Carruthers, S.
    Goater, M.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 (11) : 1626 - 1629
  • [3] Beest FJAPV, 2008, CURR MED RES OPIN, V24, P1337, DOI [10.1185/030079908X297358, 10.1185/030079908X297358 ]
  • [4] Adherence to bisphosphonate treatment by elderly women
    Berecki-Gisolf, Janneke
    Hockey, Richard
    Dobson, Annette
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2008, 15 (05): : 984 - 990
  • [5] Improving adherence to and persistence with oral therapy of osteoporosis
    Bianchi, M. L.
    Duca, P.
    Vai, S.
    Guglielmi, G.
    Viti, R.
    Battista, C.
    Scillitani, A.
    Muscarella, S.
    Luisetto, G.
    Camozzi, V.
    Nuti, R.
    Caffarelli, C.
    Gonnelli, S.
    Albanese, C.
    De Tullio, V.
    Isaia, G.
    D'Amelio, P.
    Broggi, F.
    Croci, M.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2015, 26 (05) : 1629 - 1638
  • [6] Characterisation of patients with postmenopausal osteoporosis in french primary Healthcare
    Blotman, Francis
    Cortet, Bernard
    Hilliquin, Pascal
    Avouac, Bernard
    Allaert, Francois-Andre
    Pouchain, Denis
    Gaudin, Anne-Francoise
    Cotte, Francois-Emery
    El Hasnaoui, Abdelkader
    [J]. DRUGS & AGING, 2007, 24 (07) : 603 - 614
  • [7] An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting -: Based on the results of the SOTI and TROPOS trials
    Borgstrom, F.
    Jonsson, B.
    Strom, O.
    Kanis, J. A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 (12) : 1781 - 1793
  • [8] The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases
    Brankin, Eamonn
    Walker, Mel
    Lynch, Niall
    Aspray, Terence
    Lis, Yvonne
    Cowell, Warren
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (07) : 1249 - 1256
  • [9] Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results
    Brask-Lindemann, D.
    Cadarette, S. M.
    Eskildsen, P.
    Abrahamsen, B.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2011, 22 (05) : 1493 - 1501
  • [10] Comparison of drug adherence rates among patients with seven different medical conditions
    Briesacher, Becky A.
    Andrade, Susan E.
    Fouayzi, Hassan
    Chan, Arnold
    [J]. PHARMACOTHERAPY, 2008, 28 (04): : 437 - 443